Predicting biomarkers that signal when mild cognitive impairment will progress to dementia.
Official title: Studies on Biomarkers for Mild Cognitive Impairment Conversion to Dementia
Run by Xuanwu Hospital, Beijing · NCT05697588 · Data updated 2026-11-12
This project will try to find blood, imaging, and brain electrical markers in people aged 50–85 with mild cognitive impairment to see who will progress to dementia over five years.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 50 Years to 85 Years |
| Sex | All |
| Enrollment | 900 (estimated) |
| Sponsor | Xuanwu Hospital, Beijing Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | February 28, 2023 |
| Main results expected | February 28, 2028 |
| Study ends | February 28, 2028 |
| Registry record updated | July 24, 2025 |
| Trial ID | NCT05697588 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 50–85 with mild cognitive impairment (MMSE 15–28, CDR ≤1) who can give informed consent and complete testing are the intended participants.
✕Probably not a fit
People whose cognitive problems are explained by other neurological or systemic diseases, who have contraindications to MRI, or who cannot complete testing or consent are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a 5-year prospective cohort enrolling 900 people with mild cognitive impairment and collecting extensive baseline and annual data. Baseline measures include demographics, clinical and neuropsychological testing (MMSE, MoCA, CDR), multi-modal neuroimaging (structural and functional MRI, DTI, FDG-PET, amyloid‑ and tau‑PET), neuroelectrophysiology (resting EEG, evoked potentials, polysomnography), and biofluids (blood, cerebrospinal fluid, urine, saliva) analyzed with methods like ELISA and SIMOA. Participants will be followed yearly and classified as MCI progression (MCI-P) or MCI stabilization (MCI-S) based on neuropsychological outcomes. Differences across clinical, imaging, electrophysiologic, and multi-omics fluid markers will be compared to identify combinations that predict conversion to dementia.
Why it matters
Potential benefit: If successful, this work could identify people at high risk earlier so clinicians can target interventions to delay or prevent dementia.
How similar studies have gone: Previous smaller studies using single biomarkers (for example imaging or fluid markers) have shown promise, but multi-modal prediction models like this have not yet been widely validated in clinical practice.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Male or female patients aged ≥50 and ≤85 years;
* Meet the diagnostic criteria for dementia or MCI; ③ Neuropsychological score: MMSE 15-28 points, CDR≤1 point; ④ The patients and their families were informed and signed the informed consent.
Exclusion Criteria:
* There are other neurological diseases that can cause brain dysfunction (such as depression, brain tumors, Parkinson's disease disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.);
* There are other systemic diseases that can cause cognitive impairment (such as hepatic insufficiency, renal insufficiency, Thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);
* Suffering from a disease that cannot cooperate with the completion of cognitive examination; ④ There are contraindications to nuclear magnetic resonance;
* There is mental and neurodevelopmental delay; ⑥ refuse to draw blood; ⑦ Refuse to sign the informed consent.
Where it's running
-
Xuan Wu Hospital of Capital Medical University
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Cuibai Wei — Xuan Wu Hospital of Capital Medical University
- Study coordinator: Cuibai Wei
- Email: weicb@xwhosp.org
- Phone: 83198319
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Home blood test for measuring p-tau217 in Alzheimer’s disease using the Tasso device
Researchers are testing whether a finger-prick style home blood collection tool can reliably measure p-tau217 for people with Alzheimer's disease, mild cognitive impairment, or amyloid- positive/negative status.
-
Digital platform for early detection of Alzheimer-related memory impairment
The platform will be tested to see if combining EEG, eye-tracking, and blood flow sensors can detect early memory-related cognitive impairment in people aged 55–80.
-
Acoustic Stimulation During Sleep for Alzheimer’s Disease
Researchers test whether playing gentle sounds during sleep can help people with Alzheimer’s disease see if their thinking improves compared with a sham sound.
-
See if multimodal biomarkers can map changes from mild cognitive impairment to dementia
This observational study tests whether clinical, blood, and brain-imaging markers can tell apart stages of cognitive decline and predict progression from mild cognitive impairment to dementia in about 600 people.
-
Satralizumab in the early treatment of NMOSD attacks: a multicenter real-world study
This study tests whether starting Satralizumab during an NMOSD attack is safe and helpful for adults with AQP4-IgG–positive NMOSD.
-
Real-World Experience With the WEB Device for Intracranial Aneurysms
This study tests how well the Woven EndoBridge device works in routine treatment of intracranial aneurysms in China across multiple centers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.